Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Immunology

Aclaris Therapeutics
Research

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor

February 12, 2025February 12, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug that acts as a covalent inhibitor of two key immune signaling kinases, ITK …

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor Read More

Aclaris Therapeutics
Strategic Combinations

Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies

November 21, 2024November 20, 2024 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has entered into an exclusive licensing agreement with Biosion, Inc., securing worldwide rights, excluding Greater China, to two promising antibody therapies. This …

Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies Read More
INOVIO Pharmaceuticals
Regional

INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment

November 18, 2024November 17, 2024 - by Timothy Alexander

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled encouraging new immunology data for its lead product candidate, INO-3107, which is designed to treat recurrent respiratory papillomatosis (RRP), a condition caused …

INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment Read More

Vittoria Biotherapeutics
Regional

Vittoria Biotherapeutics’ Senza5 Platform Featured in Science Immunology

July 24, 2024July 23, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Vittoria Biotherapeutics announced a significant publication by University of Pennsylvania investigators in Science Immunology. The paper highlights the role of CD5, an immunomodulatory protein, in enhancing engineered …

Vittoria Biotherapeutics’ Senza5 Platform Featured in Science Immunology Read More
Johnson & Johnson
Regional

Johnson & Johnson Seeks FDA Approval for TREMFYA in Treating Crohn’s Disease

June 25, 2024June 24, 2024 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of TREMFYA® …

Johnson & Johnson Seeks FDA Approval for TREMFYA in Treating Crohn’s Disease Read More

PharmaForce International
Regional

PharmaForce International Releases 2023 Immunology Report

June 24, 2024June 23, 2024 - by Timothy Alexander

READING, PA — PharmaForce International (PFI) has published its annual competitive intelligence report on the commercial operations of leading Immunology sales and marketing organizations in the United States. The latest …

PharmaForce International Releases 2023 Immunology Report Read More
Cabaletta Bio
Regional

Cabaletta Bio Reports Promising Early Results for New Autoimmune Disease Treatment

June 14, 2024June 14, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released positive preliminary clinical data from its Phase 1/2 trials of CABA-201, a new potential treatment option for patients with autoimmune …

Cabaletta Bio Reports Promising Early Results for New Autoimmune Disease Treatment Read More

ArriVent BioPharma
Strategic Combinations

ArriVent BioPharma Partners with Alphamab to Develop Cutting-Edge Cancer Treatments

June 6, 2024June 5, 2024 - by Timothy Alexander

SUZHOU, China and NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. announced a strategic collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”) to develop and commercialize novel antibody drug conjugates (ADCs) …

ArriVent BioPharma Partners with Alphamab to Develop Cutting-Edge Cancer Treatments Read More
The Wistar Institute
Cancer / Regional

New Hope for Tough Kidney Cancer: Reinventing Antibody Therapies

June 5, 2024June 4, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Advanced clear cell renal cell carcinoma (ccRCC) is a formidable form of kidney cancer, causing an alarming mortality rate as even recent immunotherapies leave survival chances in …

New Hope for Tough Kidney Cancer: Reinventing Antibody Therapies Read More
Century Therapeutics
Regional

Revolutionary Leap in Biotherapy: Century Therapeutics’ Ground-Breaking Technology Proves Promising

May 12, 2024May 11, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Emerging from the recent ASGCT 27th Annual Meeting, Century Therapeutics (NASDAQ: IPSC) has caught the attention of the medical world. The company revealed its innovative Allo-Evasion™ platform, …

Revolutionary Leap in Biotherapy: Century Therapeutics’ Ground-Breaking Technology Proves Promising Read More

Posts pagination

1 2 Next

Trending News

  • Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences

  • $56M Surge Targets Crumbling Campuses at 13 Pennsylvania Community Colleges

  • Dangerous Arctic Cold Grips Chester County Before a Slow Thaw Sets In

  • From Fight Calls to Child Abuse Allegation, Wyomissing Police Handle 21 Incidents

  • Education Dept. Draws New Lines on School Prayer, Launches Student Data Probe

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Police News

From Fight Calls to Child Abuse Allegation, Wyomissing Police Handle 21 Incidents

19 hours ago19 hours ago

US Department of Health and Human Services (HHS)

HHS Unleashes Sweeping Recovery Plan Targeting Addiction, Homelessness

February 7, 2026February 7, 2026

Department of Veterans Affairs

VA Expands Home Care, Hires Counselors, Warns as Veteran Suicide Toll Eases

February 7, 2026February 7, 2026

Copyright © 2026 MyChesCo.